More MS news articles for April 2000

Neurocrine, Teva, Punctuate Look at MS Drugs on BioTalk Today in Wake of Soft

Avonex Sales at Biogen

ROSEVILLE, Calif., April 12 /PRNewswire/ -- Sales of Biogen's (Nasdaq: BGEN) drug for Multiple Sclerosis (MS), Avonex, fell short of analysts' expectations and dragged the stock lower yesterday following its earnings announcement, so BioTalk, the global investor's direct source for understanding the biotech industry from, reviews the MS drug market today with emerging player Neurocrine (Nasdaq: NBIX) and acquisitive Teva Pharmaceuticals (Nasdaq: TEVA), maker of Copaxone, and others.

Tune to the show from 11 a.m.-noon EDT at or, or via dial at WMET 1150 AM in Gaithersburg, MD.  Listeners can send questions in real-time via email during the show to cohost Tim Quast at

Four drugs dominate the MS market currently, including Biogen's Avonex, for relapsing-remitting MS.  Sales of the drug in the most recent quarter were weaker than expected, and the stock dropped 12 points on 20 million shares traded, to 53.  Invited radio guest Omar Khan, M.D., director of experimental therapeutics and research at Wayne State University MS Center, found that early-stage MS patients showed statistically significant improvement in disability scores with Betaseron(R) and Copaxone(R), while those receiving treatment with Avonex(R) showed no significant improvement during the 12-month period of the study. Invited guest Chiron (Nasdaq: CHIR) (unable to appear on the show due to scheduling conflicts) and Berlex Laboratories, a division of Schering AG (Frankfurt: SCH.F), manufacture and market Betaseron, respectively.

The study was partially underwritten by TevaMarion, a joint venture between Teva Pharmaceuticals and Marion Merrill Dow, which makes Copaxone.

BioTalk will focus on how these drugs, and Rebif, from Swiss-based Ares-Serono, act and are administered in comparison to each other, and where MS therapies are currently headed. is the leading producer of online and offline industry-specific investment conferences for individual investors and offers a growing stable of resources for in-depth analysis of the internet, technology and biotechnology sectors, including BioTalk, a weekly radio show bringing investors deep insights on the biotech sector.


CO:; Teva Pharmaceutical Industries Limited; Biogen, Inc.; Neurocrine Biosciences, Inc.